JP2006522023A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006522023A5 JP2006522023A5 JP2006503706A JP2006503706A JP2006522023A5 JP 2006522023 A5 JP2006522023 A5 JP 2006522023A5 JP 2006503706 A JP2006503706 A JP 2006503706A JP 2006503706 A JP2006503706 A JP 2006503706A JP 2006522023 A5 JP2006522023 A5 JP 2006522023A5
- Authority
- JP
- Japan
- Prior art keywords
- methoxyphenyl
- dichloro
- amino
- methoxy
- ethoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 claims 15
- 230000000302 ischemic effect Effects 0.000 claims 11
- 230000007213 cerebrovascular event Effects 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 7
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims 6
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 229940079593 drug Drugs 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 230000008728 vascular permeability Effects 0.000 claims 3
- NPTUGALLOCBPCM-UHFFFAOYSA-N 4-(2,4-dichloro-5-methoxyanilino)-6-ethoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinoline-3-carbonitrile Chemical compound N#CC1=CN=C2C=C(OCC3CCN(C)CC3)C(OCC)=CC2=C1NC1=CC(OC)=C(Cl)C=C1Cl NPTUGALLOCBPCM-UHFFFAOYSA-N 0.000 claims 2
- JQGPWNQWNMMMAS-UHFFFAOYSA-N 4-(2,4-dichloro-5-methoxyanilino)-6-ethoxy-7-[2-(1-methylpiperidin-4-yl)ethoxy]quinoline-3-carbonitrile Chemical compound N#CC1=CN=C2C=C(OCCC3CCN(C)CC3)C(OCC)=CC2=C1NC1=CC(OC)=C(Cl)C=C1Cl JQGPWNQWNMMMAS-UHFFFAOYSA-N 0.000 claims 2
- OSJKQGUEJYZHQM-UHFFFAOYSA-N 4-(2,4-dichloro-5-methoxyanilino)-6-ethoxy-7-[3-(1-methylpiperidin-4-yl)propoxy]quinoline-3-carbonitrile Chemical compound N#CC1=CN=C2C=C(OCCCC3CCN(C)CC3)C(OCC)=CC2=C1NC1=CC(OC)=C(Cl)C=C1Cl OSJKQGUEJYZHQM-UHFFFAOYSA-N 0.000 claims 2
- FCIILWHQWNLPJU-UHFFFAOYSA-N 4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-[2-(1-methylpiperidin-4-yl)ethoxy]quinoline-3-carbonitrile Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCCC4CCN(C)CC4)C=C3N=CC=2C#N)=C1Cl FCIILWHQWNLPJU-UHFFFAOYSA-N 0.000 claims 2
- QXWCRBMAGJJKTO-UHFFFAOYSA-N 4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-[3-(1-methylpiperidin-4-yl)propoxy]quinoline-3-carbonitrile Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCCCC4CCN(C)CC4)C=C3N=CC=2C#N)=C1Cl QXWCRBMAGJJKTO-UHFFFAOYSA-N 0.000 claims 2
- HOHWAQXKWAAULM-UHFFFAOYSA-N 4-(2,4-dichloro-5-methoxyanilino)-7-[(1-ethylpiperidin-4-yl)methoxy]-6-methoxyquinoline-3-carbonitrile Chemical compound C1CN(CC)CCC1COC1=CC2=NC=C(C#N)C(NC=3C(=CC(Cl)=C(OC)C=3)Cl)=C2C=C1OC HOHWAQXKWAAULM-UHFFFAOYSA-N 0.000 claims 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 claims 2
- 206010021143 Hypoxia Diseases 0.000 claims 2
- 206010061216 Infarction Diseases 0.000 claims 2
- 210000004204 blood vessel Anatomy 0.000 claims 2
- 230000002490 cerebral effect Effects 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 230000007574 infarction Effects 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- 208000028867 ischemia Diseases 0.000 claims 2
- 230000007971 neurological deficit Effects 0.000 claims 2
- 230000004112 neuroprotection Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 125000004484 1-methylpiperidin-4-yl group Chemical group CN1CCC(CC1)* 0.000 claims 1
- -1 2,4-dichloro-5-methoxyphenyl Chemical group 0.000 claims 1
- PCSXTJQETYJEOI-UHFFFAOYSA-N 4-(2,4-dichloro-5-methoxyanilino)-6-ethoxy-7-[2-(4-methylpiperazin-1-yl)ethoxy]quinoline-3-carbonitrile Chemical compound N#CC1=CN=C2C=C(OCCN3CCN(C)CC3)C(OCC)=CC2=C1NC1=CC(OC)=C(Cl)C=C1Cl PCSXTJQETYJEOI-UHFFFAOYSA-N 0.000 claims 1
- FEPWXPAVJHFWGS-UHFFFAOYSA-N 4-(2,4-dichloro-5-methoxyanilino)-6-ethoxy-7-[3-(4-ethylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile Chemical compound N#CC1=CN=C2C=C(OCCCN3CCN(CC)CC3)C(OCC)=CC2=C1NC1=CC(OC)=C(Cl)C=C1Cl FEPWXPAVJHFWGS-UHFFFAOYSA-N 0.000 claims 1
- SNJXHAGNHXWXDO-UHFFFAOYSA-N 4-(2,4-dichloro-5-methoxyanilino)-6-ethoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile Chemical compound N#CC1=CN=C2C=C(OCCCN3CCN(C)CC3)C(OCC)=CC2=C1NC1=CC(OC)=C(Cl)C=C1Cl SNJXHAGNHXWXDO-UHFFFAOYSA-N 0.000 claims 1
- TXAYKQMEBQBGLR-UHFFFAOYSA-N 4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinoline-3-carbonitrile Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCC4CCN(C)CC4)C=C3N=CC=2C#N)=C1Cl TXAYKQMEBQBGLR-UHFFFAOYSA-N 0.000 claims 1
- UNVLTPQRCHRNDB-UHFFFAOYSA-N 4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-[2-(4-methylpiperazin-1-yl)ethoxy]quinoline-3-carbonitrile Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCCN4CCN(C)CC4)C=C3N=CC=2C#N)=C1Cl UNVLTPQRCHRNDB-UHFFFAOYSA-N 0.000 claims 1
- SUGCHLACYQMXHH-UHFFFAOYSA-N 4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-[3-(4-propylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile Chemical compound C1CN(CCC)CCN1CCCOC1=CC2=NC=C(C#N)C(NC=3C(=CC(Cl)=C(OC)C=3)Cl)=C2C=C1OC SUGCHLACYQMXHH-UHFFFAOYSA-N 0.000 claims 1
- JYNBIMGGLJKDLR-UHFFFAOYSA-N 4-(2,4-dichloro-5-methoxyanilino)-7-[2-(4-ethylpiperazin-1-yl)ethoxy]-6-methoxyquinoline-3-carbonitrile Chemical compound C1CN(CC)CCN1CCOC1=CC2=NC=C(C#N)C(NC=3C(=CC(Cl)=C(OC)C=3)Cl)=C2C=C1OC JYNBIMGGLJKDLR-UHFFFAOYSA-N 0.000 claims 1
- BIEFBSIFAKMKOT-UHFFFAOYSA-N 4-(2,4-dichloro-5-methoxyanilino)-7-[3-(4-ethylpiperazin-1-yl)propoxy]-6-methoxyquinoline-3-carbonitrile Chemical compound C1CN(CC)CCN1CCCOC1=CC2=NC=C(C#N)C(NC=3C(=CC(Cl)=C(OC)C=3)Cl)=C2C=C1OC BIEFBSIFAKMKOT-UHFFFAOYSA-N 0.000 claims 1
- 206010002660 Anoxia Diseases 0.000 claims 1
- 241000976983 Anoxia Species 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 206010018985 Haemorrhage intracranial Diseases 0.000 claims 1
- 206010019196 Head injury Diseases 0.000 claims 1
- 208000010496 Heart Arrest Diseases 0.000 claims 1
- 208000008574 Intracranial Hemorrhages Diseases 0.000 claims 1
- 206010028923 Neonatal asphyxia Diseases 0.000 claims 1
- 208000037212 Neonatal hypoxic and ischemic brain injury Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 230000007953 anoxia Effects 0.000 claims 1
- UBPYILGKFZZVDX-UHFFFAOYSA-N bosutinib Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCCCN4CCN(C)CC4)C=C3N=CC=2C#N)=C1Cl UBPYILGKFZZVDX-UHFFFAOYSA-N 0.000 claims 1
- 238000010276 construction Methods 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 230000007954 hypoxia Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 208000033300 perinatal asphyxia Diseases 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 208000005809 status epilepticus Diseases 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 230000001052 transient effect Effects 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 0 COc(c(Cl)c1)cc(Nc(c(cc(c(OC*2CCN(*)CC2)c2)O*)c2nc2)c2C#N)c1Cl Chemical compound COc(c(Cl)c1)cc(Nc(c(cc(c(OC*2CCN(*)CC2)c2)O*)c2nc2)c2C#N)c1Cl 0.000 description 2
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US44931603P | 2003-02-21 | 2003-02-21 | |
| PCT/US2004/004904 WO2004075898A1 (en) | 2003-02-21 | 2004-02-19 | 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-3-quinolinecarbonitriles for the treatment of ischemic injury |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006522023A JP2006522023A (ja) | 2006-09-28 |
| JP2006522023A5 true JP2006522023A5 (enExample) | 2008-08-21 |
Family
ID=32927510
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006503706A Withdrawn JP2006522023A (ja) | 2003-02-21 | 2004-02-19 | 虚血損傷治療のための４−［（２，４−ジクロロ−５−メトキシフェニル）アミノ］−６−アルコキシ−３−キノリンカルボニトリル |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20040229880A1 (enExample) |
| EP (1) | EP1594502A1 (enExample) |
| JP (1) | JP2006522023A (enExample) |
| KR (1) | KR20050102133A (enExample) |
| CN (1) | CN1750824A (enExample) |
| AR (1) | AR043253A1 (enExample) |
| AU (1) | AU2004216235A1 (enExample) |
| BR (1) | BRPI0407441A (enExample) |
| CA (1) | CA2516418A1 (enExample) |
| CO (1) | CO5640114A2 (enExample) |
| CR (1) | CR7931A (enExample) |
| EC (1) | ECSP055972A (enExample) |
| MX (1) | MXPA05008706A (enExample) |
| NO (1) | NO20054070L (enExample) |
| RU (1) | RU2005129333A (enExample) |
| TW (1) | TW200423938A (enExample) |
| UA (1) | UA80472C2 (enExample) |
| WO (1) | WO2004075898A1 (enExample) |
| ZA (1) | ZA200506621B (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG146681A1 (en) * | 2003-11-06 | 2008-10-30 | Wyeth Corp | 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (cml) |
| RU2007111704A (ru) * | 2004-10-22 | 2008-11-27 | Вайет (Us) | 4[(2,4-дихлоро-5-метоксифенил)амино]-6-алкокси-7-этинил-3-хинолинкарбонитрилы для лечения ишемического поражения |
| MX2008000384A (es) * | 2005-07-01 | 2008-03-07 | Wyeth Corp | Formas cristalinas de 4-[(2,4-dicloro-5-metoxifenil)amino]-6-metox i-7-[3-(4-metil-1-piperazinil)propoxi]-3-quinolinocarbonitrilo y metodos para su preparacion. |
| MX342879B (es) | 2010-07-30 | 2016-10-14 | Oncotherapy Science Inc * | Derivados de quinolina e inhibidores de cinasa de cremallera de leucina embrionica materna que los contienen. |
| CN103772392A (zh) * | 2012-10-23 | 2014-05-07 | 杨子娇 | 一类治疗房角狭窄的化合物及其用途 |
| IN2014CH00840A (enExample) | 2014-02-20 | 2015-09-18 | Apotex Inc | |
| TWI672141B (zh) | 2014-02-20 | 2019-09-21 | 美商醫科泰生技 | 投予ｒｏｓ１突變癌細胞之分子 |
| US20160256457A1 (en) * | 2014-06-10 | 2016-09-08 | Beth Israel Deaconess Medical Center, Inc. | Methods for treating or preventing acute vascular leak |
| AU2015355220B2 (en) | 2014-12-02 | 2020-02-27 | Ignyta, Inc. | Combinations for the treatment of neuroblastoma |
| WO2017029584A1 (en) * | 2015-08-19 | 2017-02-23 | Sun Pharmaceutical Industries Limited | Amorphous form of bosutinib |
| KR20180096621A (ko) | 2015-12-18 | 2018-08-29 | 이그니타, 인코포레이티드 | 암의 치료용 조합물 |
| CN107814769B (zh) * | 2016-09-14 | 2021-05-07 | 正大天晴药业集团股份有限公司 | 一种博舒替尼的纯化方法 |
| WO2019018570A1 (en) | 2017-07-19 | 2019-01-24 | Ignyta, Inc. | PHARMACEUTICAL COMPOSITIONS CONTAINING ENTRECTINIB |
| JP7311498B2 (ja) | 2017-10-17 | 2023-07-19 | イグナイタ インコーポレイテッド | 薬学的組成物および剤形 |
| CN111646940B (zh) * | 2019-03-04 | 2024-01-30 | 鲁南制药集团股份有限公司 | 一种博舒替尼中间体的制备方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6002008A (en) * | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
| US6297258B1 (en) * | 1998-09-29 | 2001-10-02 | American Cyanamid Company | Substituted 3-cyanoquinolines |
| US6521618B2 (en) * | 2000-03-28 | 2003-02-18 | Wyeth | 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors |
| TWI275390B (en) * | 2002-04-30 | 2007-03-11 | Wyeth Corp | Process for the preparation of 7-substituted-3- quinolinecarbonitriles |
| US20060167021A1 (en) * | 2002-10-04 | 2006-07-27 | Caritas St. Elizabeth's Medical Center Of Boston, Inc. | Inhibition of src for treatment of reperfusion injury related to revascularization |
-
2004
- 2004-02-18 US US10/780,973 patent/US20040229880A1/en not_active Abandoned
- 2004-02-18 TW TW093103901A patent/TW200423938A/zh unknown
- 2004-02-19 AU AU2004216235A patent/AU2004216235A1/en not_active Withdrawn
- 2004-02-19 BR BR0407441-6A patent/BRPI0407441A/pt not_active IP Right Cessation
- 2004-02-19 CN CNA2004800046743A patent/CN1750824A/zh active Pending
- 2004-02-19 JP JP2006503706A patent/JP2006522023A/ja not_active Withdrawn
- 2004-02-19 EP EP04712889A patent/EP1594502A1/en not_active Withdrawn
- 2004-02-19 RU RU2005129333/04A patent/RU2005129333A/ru not_active Application Discontinuation
- 2004-02-19 MX MXPA05008706A patent/MXPA05008706A/es unknown
- 2004-02-19 UA UAA200508924A patent/UA80472C2/uk unknown
- 2004-02-19 KR KR1020057015377A patent/KR20050102133A/ko not_active Withdrawn
- 2004-02-19 CA CA002516418A patent/CA2516418A1/en not_active Abandoned
- 2004-02-19 WO PCT/US2004/004904 patent/WO2004075898A1/en not_active Ceased
- 2004-02-20 AR ARP040100546A patent/AR043253A1/es not_active Application Discontinuation
-
2005
- 2005-08-03 CR CR7931A patent/CR7931A/es not_active Application Discontinuation
- 2005-08-17 CO CO05081472A patent/CO5640114A2/es not_active Application Discontinuation
- 2005-08-18 ZA ZA200506621A patent/ZA200506621B/en unknown
- 2005-08-19 EC EC2005005972A patent/ECSP055972A/es unknown
- 2005-09-01 NO NO20054070A patent/NO20054070L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006522023A5 (enExample) | ||
| JP6021805B2 (ja) | 腫瘍治療剤 | |
| JP2006523216A5 (enExample) | ||
| JP2022518456A (ja) | 置換多環式カルボン酸、その類似体、およびそれらの使用法 | |
| JP2007533687A (ja) | 月経前の及び他の女性の性的障害の治療におけるフリバンセリンの使用 | |
| JP2008540672A (ja) | 病状に起因する性的機能不全の治療方法 | |
| CN105012303A (zh) | (αS,βR)-6-溴-α-[2-(二甲胺基)乙基]-2-甲氧基-α-1-萘基-β-苯基-3-喹啉乙醇的富马酸盐 | |
| JP2002506815A (ja) | ＧＡＢＡＡα５逆作動薬とアセチルコリンエステラーゼ阻害剤との組合わせ | |
| RU2005129333A (ru) | 4-[(2,4-дихлор-5-метоксифенил)амино]-6-алкокси-3-хинолинкарбонитрилы для лечения ишемического повреждения | |
| US20120238591A1 (en) | Acyclovir formulations | |
| TW201912153A (zh) | 用於治療ｂ型肝炎的化合物、醫藥組合物及方法 | |
| JP2006518731A5 (enExample) | ||
| JP2009525265A5 (enExample) | ||
| AU2008259864C1 (en) | Methods and compositions for administration of Oxybutynin | |
| JP2008521934A5 (enExample) | ||
| US8748488B2 (en) | Methods and compositions for administration of oxybutynin | |
| TW202304914A (zh) | 經取代之四環羧酸、其類似物及使用其之方法 | |
| WO2014152317A2 (en) | Methods of treating gonorrhea infections using quinolone antibiotics | |
| JP2008517924A5 (enExample) | ||
| JP6025886B2 (ja) | 慢性疼痛治療剤 | |
| JP2002541190A (ja) | 気分障害治療用医薬を製造するためのオサネタントの使用 | |
| CN117979999A (zh) | 使用btk抑制剂和pi3激酶抑制剂的组合治疗癌症的方法 | |
| JP2005529110A5 (enExample) | ||
| Trivedi et al. | Nintedanib as the First Treatment for Group of Progressive Interstitial Lung Diseases: A Review of Patent Literature | |
| WO2017145089A1 (en) | Crystalline form x of bosutinib |